Immune synergistic oligodeoxynucleotide from <i>Lactobacillus rhamnosus </i><scp>GG</scp> enhances the immune response upon co‐stimulation by bacterial and fungal cell wall components

Nigar, Shireen; Yamamoto, Yuroku; Okajima, Takuma; Sato, Takashi; Ogita, Tasuku; Shimosato, Takeshi

doi:10.1111/asj.13082

Cited by 5 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have confirmed that TLR1 to TLR9 all exist in IECs [130], but the exact mechanisms of TLRs underlying the regulation of intestinal homeostasis have yet to be fully illuminated. Bacterial cell walls lipoproteins, bacterial peptidoglycan, and fungal zymosan are recognized by TLR1, TLR2, and TLR6, respectively [131,132,133]. TLR4 is responsible for recognizing LPS produced by Gram-negative bacteria.…”

Section: Orchestrated Balance Between Mucosal Immune System and Gumentioning

confidence: 99%

Inflammatory Bowel Disease: A Potential Result from the Collusion between Gut Microbiota and Mucosal Immune System

Yue

et al. 2019

Microorganisms

View full text Add to dashboard Cite

Host health depends on the intestinal homeostasis between the innate/adaptive immune system and the microbiome. Numerous studies suggest that gut microbiota are constantly monitored by the host mucosal immune system, and any slight disturbance in the microbial communities may contribute to intestinal immune disruption and increased susceptibility to inflammatory bowel disease (IBD), a chronic relapsing inflammatory condition of the gastrointestinal tract. Therefore, maintaining intestinal immune homeostasis between microbiota composition and the mucosal immune system is an effective approach to prevent and control IBD. The overall theme of this review is to summarize the research concerning the pathogenesis of IBD, with particular focus on the factors of gut microbiota-mucosal immune interactions in IBD. This is a comprehensive and in-depth report of the crosstalk between gut microbiota and the mucosal immune system in IBD pathogenesis, which may provide insight into the further evaluation of the therapeutic strategies for IBD.

show abstract

Section: Orchestrated Balance Between Mucosal Immune System and Gumentioning

confidence: 99%

Inflammatory Bowel Disease: A Potential Result from the Collusion between Gut Microbiota and Mucosal Immune System

Yue

et al. 2019

Microorganisms

View full text Add to dashboard Cite

show abstract

“…The cells were subsequently incubated with different concentrations (2 × 10 6 and 2 × 10 7 CFU per well) of heat‐killed LIC37 (experimental) or LGG (control) for 2 hr before being stimulated with lipopolysaccharide (LPS, Sigma‐Aldrich) (100 ng/well) or with DMEM as a negative control. Intracellular levels of the transcripts encoding tumor necrosis factor (TNF)‐α, interleukin (IL)‐6, and IL‐10 and secretion of the corresponding proteins were assessed by real‐time quantitative PCR (RT‐qPCR) (Namai, Yamamoto, Sato, Ogita, & Shimosato, 2018; Nigar et al., 2018) and ELISA, respectively.…”

Section: Methodsmentioning

confidence: 99%

Lactobacillus ingluviei C37 from chicken inhibits inflammation in LPS‐stimulated mouse macrophages

Tsukagoshi

Sirisopapong

Namai

et al. 2020

Animal Science Journal

Self Cite

View full text Add to dashboard Cite

Over the last few decades, antibiotics have been widely used in animal production to enhance livestock growth and/or to prevent and treat disease (Bengtsson & Greko, 2014). At the same time, the global use of antibiotics has contributed to an increase in antibiotic-resistant bacteria, which can be transmitted to human beings (Garcia et al., 2020). The rise of antibiotic resistance is a worldwide threat, with an estimated death rate of 700,000 deaths per year and a predicted 10,000,000 deaths by 2050 (Interagency Coordination Group on Antimicrobial Resistance, 2019). As a result, the use of antibiotics has been restricted in many countries, following a ban on use for animal growth promotion in Sweden in 1986 (Mingmongkolchai & Panbangred, 2018). Consequently, there is a growing interest in alternatives to antibiotics, including probiotic lactic acid bacteria (LAB; Hiruta, 2015). Labs are widely distributed in nature and have a long history of safe consumption as animal feed or human food. Recently, various species and strains of LAB have been recognized as probiotics, a term that refers to a "live microorganism[s] which when administered in adequate amounts confer a health benefit on the host" (Hill et al., 2014). Some species and strains even exert (in their dead form) health-promoting effects on the host, a phenomenon called paraprobiotics (Taverniti & Guglielmetti, 2011). When alive, probiotics can produce antimicrobial substances, adhere to the intestine, and compete with other bacteria, thereby inhibiting colonization by pathogenic bacteria and improving the intestinal environment. Probiotics also can modulate the immune responses and gastrointestinal

show abstract

“…In 2017, Nigar et al explored a novel ODN (named “iSN34”) incorporated into Lactobacillus rhamnosus , GGATCC53108, that has synergistic effects on the immune response in CpG-induced immune activation (47). The iSN34 sequence is TTCCTAAGCTTGAGGCCT (48). Originally, we evaluated inhibitory or suppressive ODN (iODNs) with a TTAGGG motif.…”

Section: Oligodeoxynucleotides As Immune Modulatorsmentioning

confidence: 99%

“…Thus, iSN34 may be an extraordinarily impressive adjuvant-mediated vaccine via Th1 that defends against intracellular pathogens, or iSN34 may provide antibody-mediated immunity compared to extracellular pathogens (47). We also conducted further investigations into the synergistic induction of IL-6 by the consolidation of iSN34 with the cell wall components of bacteria (TLR1/TLR2, TLR4) and fungi (TLR2/TLR6) (48). This review focuses on the synergistic immune effects of combining CpG ODNs with synthetic molecules associated with TLR ligands targeting inflammation and autoimmune diseases.…”

Section: Oligodeoxynucleotides As Immune Modulatorsmentioning

confidence: 99%

“…Thus, the synergistic effects of CpG ODNs enhance both Th1 and Th2 responses and advances maturation of APCs. This review demonstrated the widespread immune response involving CpG and different synthetic molecules such as granulocyte-macrophage colony-stimulating factor (112), IL-15 (113), the STING ligand (114), Gardiquimod (115), IL-10 siRNA (116), poly (I:C) (57, 117, 118), encapsulated poly(γ-PGA-Phe) (119), imiquimod (120, 121), TLR2-neutralizing antibody (95), and iSN34 (47, 48) (Table 1). Furthermore, the application of CpG ODNs and synthetic molecules as adjuvant treatment was demonstrated to improve immunity even in cases with weakened immune systems.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators

Nigar¹,

Shimosato

2019

Front. Nutr.

Self Cite

View full text Add to dashboard Cite

Unmethylated cytosine–guanine dinucleotide (CpG) motifs are potent stimulators of the host immune response. Cellular recognition of CpG motifs occurs via Toll-like receptor 9 (TLR9), which normally activates immune responses to pathogen-associated molecular patterns (PAMPs) indicative of infection. Oligodeoxynucleotides (ODNs) containing unmethylated CpGs mimic the immunostimulatory activity of viral/microbial DNA. Synthetic ODNs harboring CpG motifs resembling those identified in viral/microbial DNA trigger an identical response, such that these immunomodulatory ODNs have therapeutic potential. CpG DNA has been investigated as an agent for the management of malignancy, asthma, allergy, and contagious diseases, and as an adjuvant in immunotherapy. In this review, we discuss the potential synergy between synthetic ODNs and other synthetic molecules and their immunomodulatory effects. We also summarize the different synthetic molecules that function as immune modulators and outline the phenomenon of TLR-mediated immune responses. We previously reported a novel synthetic ODN that acts synergistically with other synthetic molecules (including CpG ODNs, the synthetic triacylated lipopeptide Pam 3 CSK 4 , lipopolysaccharide, and zymosan) that could serve as an immune therapy. Additionally, several clinical trials have evaluated the use of CpG ODNs with other immune factors such as granulocyte-macrophage colony-stimulating factor, cytokines, and both endosomal and cell-surface TLR ligands as adjuvants for the augmentation of vaccine activity. Furthermore, we discuss the structural recognition of ODNs by TLRs and the mechanism of functional modulation of TLRs in the context of the potential application of ODNs as wide-spectrum therapeutic agents.

show abstract

Immune synergistic oligodeoxynucleotide from Lactobacillus rhamnosus GG enhances the immune response upon co‐stimulation by bacterial and fungal cell wall components

Cited by 5 publications

References 36 publications

Inflammatory Bowel Disease: A Potential Result from the Collusion between Gut Microbiota and Mucosal Immune System

Inflammatory Bowel Disease: A Potential Result from the Collusion between Gut Microbiota and Mucosal Immune System

Lactobacillus ingluviei C37 from chicken inhibits inflammation in LPS‐stimulated mouse macrophages

Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators

Contact Info

Product

Resources

About